 |
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-927
Therapeutic area:
Cancer
|
|
AbbVie |
Atrasentan |
Biodrugs/ Drugs |
Kidney and Genitourinary system |
Diabetic Nephropathy |
3PhIII |
Atrasentan
Therapeutic area:
Kidney and Genitourinary system
|
|
AbbVie |
ABT-494 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis / Chron Disease / Ulcerative Colitis/ Atopic Dermatitis / Psoriasic Arthritis / Axial Spondiloarthritis / Giant Cell Artheritis / Juvenil Idiopatic Arthritis |
3PhIII |
ABT-494
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-221 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-221
Therapeutic area:
Cancer
|
|
AbbVie |
Humira (adalimumab) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Hidradenitis Suppurativa / Uveitis / Ulcerative colitis/ Chron Disease / Rheumatoid Arthritis / Psoriasis / Psoriatic Arthritis |
4Reg. |
Humira (adalimumab)
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-927 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-927
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-199/GDC0199 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Chronic Lymphocytic Leukemia / Mieloma Multiple / Leucemia Mieloide Aguda |
3PhIII |
ABT-199/GDC0199
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
AbbVie |
ABT-414 |
Biodrugs/ Drugs |
Cancer |
Relapsed GBM / Incipient GBM |
3PhIII |
ABT-414
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-066 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Psoriasis, Psoriatic arthritis, Crohn disease, Ulcerative colitis |
3PhIII |
ABT-066
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
HCV Interferon-Free Combination (genotype 1) |
Biodrugs/ Drugs |
Infections |
haepatitis C |
3PhIII |
HCV Interferon-Free Combination (genotype 1)
Therapeutic area:
Infections
|
|
AbbVie |
ABBV-838 |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
1PhI |
ABBV-838
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-122 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Psoriasic arthritis |
2PhII |
ABT-122
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
Veliparib |
Biodrugs/ Drugs |
Cancer |
Breast Cancer / NSCLC / SCLC / ovarian cancer / TNBC / colorectal cancer / Brain cancer |
3PhIII |
Veliparib
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-181 |
Biodrugs/ Drugs |
Cancer |
Cáncer de cabeza, cuello y mama |
1PhI |
ABBV-181
Therapeutic area:
Cancer
|
|
AbbVie |
ABV-085 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABV-085
Therapeutic area:
Cancer
|
|
AbbVie |
Rova-T |
Biodrugs/ Drugs |
Cancer |
NSCLC |
3PhIII |
Rova-T
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-621 |
Biodrugs/ Drugs |
Cancer |
Cancer colorrectal, Leucemia Mieloide aguda |
1PhI |
ABBV-621
Therapeutic area:
Cancer
|
|
AbbVie |
ABT-SLV187 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
4Reg. |
ABT-SLV187
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-399 |
Biodrugs/ Drugs |
Cancer |
NSCLC |
2PhII |
ABBV-399
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-323 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
ABBV-323
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABBV-8E12 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer / PSP |
2PhII |
ABBV-8E12
Therapeutic area:
Central Nervous System
|
|
AbbVie |
ABBV-559 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis |
2PhII |
ABBV-559
Therapeutic area:
Autoimmune & Inflammation
|
|
AbbVie |
ABT-165 |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
2PhII |
ABT-165
Therapeutic area:
Cancer
|
|
AbbVie |
ABBV-176 |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
ABBV-176
Therapeutic area:
Cancer
|
 |
Amgen |
Evolocumab |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia |
4Reg. |
Evolocumab
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Amgen |
AMG 757 |
Biodrugs/ Drugs |
Cancer |
Cáncer de pulmón de células pequeñas |
1PhI |
AMG 757
Therapeutic area:
Cancer
|
|
Amgen |
AMG 820 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
AMG 820
Therapeutic area:
Cancer
|
|
Amgen |
Talimogene laherparepvec |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma |
4Reg. |
Talimogene laherparepvec
Therapeutic area:
Cancer
|
|
Amgen |
Denosumab |
Biodrugs/ Drugs |
Cancer |
Giant cell tumour of the bone |
2PhII |
Denosumab
Therapeutic area:
Cancer
|
|
Amgen |
AMG 596 |
Biodrugs/ Drugs |
Central Nervous System |
Glioblastoma |
1PhI |
AMG 596
Therapeutic area:
Central Nervous System
|
|
Amgen |
oprozomib |
Biodrugs/ Drugs |
Cancer |
Mieloma |
2PhII |
oprozomib
Therapeutic area:
Cancer
|
|
Amgen |
Cinacalcet |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT |
4Reg. |
Cinacalcet
Therapeutic area:
Autoimmune & Inflammation / Kidney and Genitourinary system
|
|
Amgen |
Omecantiv mecarbil |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure |
3PhIII |
Omecantiv mecarbil
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Amgen |
AMG 592 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Artritis reumatoide |
2PhII |
AMG 592
Therapeutic area:
Autoimmune & Inflammation
|
|
Amgen |
Romiplostim |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) |
4Reg. |
Romiplostim
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Tezepelumab |
Biodrugs/ Drugs |
Dermatology
Respiratory and Pulmonary system |
Asma corticoide dependiente
Dermatitis atópica |
3PhIII |
Tezepelumab
Therapeutic area:
Dermatology / Respiratory and Pulmonary system
|
|
Amgen |
Vectibix |
Biodrugs/ Drugs |
Cancer |
Cancer colorrectal metastásico |
4Reg. |
Vectibix
Therapeutic area:
Cancer
|
|
Amgen |
Etelcalcetide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Secondary Hyperparathyroidism |
4Reg. |
Etelcalcetide
Therapeutic area:
Metabolic / Endocrinology
|
|
Amgen |
Kanjinti |
Biodrugs/ Drugs |
Cancer |
Cáncer de mama HER2+ precoz y metastásico |
4Reg. |
Kanjinti
Therapeutic area:
Cancer
|
|
Amgen |
Romosozumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders
Women´s health |
Postmenopausal osteoporosis |
3PhIII |
Romosozumab
Therapeutic area:
Musculoskeletal Disorders / Women´s health
|
|
Amgen |
ABP 959 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Hemoglobinuria paroxística nocturna |
3PhIII |
ABP 959
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Denosumab |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer |
4Reg. |
Denosumab
Therapeutic area:
Musculoskeletal Disorders
|
|
Amgen |
ABP 798 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Linfoma no-Hodgkin |
3PhIII |
ABP 798
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Blinatumomab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute lymphoblastic leukaemia |
4Reg. |
Blinatumomab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Amgen |
AMG 397 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Leucemia Mieloide Aguda
Linfoma no-Hodgkin
Mieloma Multiple |
1PhI |
AMG 397
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
AMG 420 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Mieloma Multiple |
1PhI |
AMG 420
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
Carfilzomib |
Biodrugs/ Drugs |
Cancer |
Mieloma |
4Reg. |
Carfilzomib
Therapeutic area:
Cancer
|
|
Amgen |
AMG 701 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Mieloma Multiple |
1PhI |
AMG 701
Therapeutic area:
Blood and Lymphatic systems
|
|
Amgen |
erenumab |
Biodrugs/ Drugs |
Central Nervous System |
Migraine |
4Reg. |
erenumab
Therapeutic area:
Central Nervous System
|
 |
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS): lower-risk
Post-induction AML maintenance |
3PhIII |
CC-486
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
PD-L1 Inhibitor:durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Multiple Myeloma (MM)
Chronic Lymphocytic Leukemia (CLL)
No-Hodgkin Lymphoma (NHL) |
1PhI |
PD-L1 Inhibitor:durvalumab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
REVLIMID ( lenalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
lymphoma: Adult T-cell leukemia- lymphoma (Japan) |
3PhIII |
REVLIMID ( lenalidomide)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC-90009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
1PhI |
CC-90009
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
BET inhibitor: CC-90010 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
BET inhibitor: CC-90010
Therapeutic area:
Cancer
|
|
Celgene |
AG-221 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
3PhIII |
AG-221
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Breast: Metastatic
Non-small cell lung: Advanced
Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure |
2PhII |
CC 486
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
PDA-002 |
Biodrugs/ Drugs |
Others |
Diabetic foot ulcers
Diabetic peripheral neuropathy |
2PhII |
PDA-002
Therapeutic area:
Others
|
|
Celgene |
OTEZLA (apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Psoriatic arthritis (PsA) Psoriasis |
4Reg. |
OTEZLA (apremilast)
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Celgene |
CC-220 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Systemic lupus erythematosus |
2PhII |
CC-220
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Avadomide (CC-122) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma. Diffuse large B-cell lymphoma |
1PhI |
Avadomide (CC-122)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
AG-120 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML) |
1PhI |
AG-120
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
OTEZLA® (Apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Ankylosing spondylitis
Behcets disease |
4Reg. |
OTEZLA® (Apremilast)
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Celgene |
PNK-007 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM) |
1PhI |
PNK-007
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
IDHIFA (enasidenib) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Myelodyplastic Syndromes (MDS) RElapsed/refractory IDH2 mutation (US) |
4Reg. |
IDHIFA (enasidenib)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC-122 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoma: Diffuse large B-Cell & Indolent lymphoma: relapsed/refractory
Hepatocellular carcinoma
Multiple Myeloma
Chronic Lymphocytic Leukemia (CLL) |
1PhI |
CC-122
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-90006 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Autoinmune disorders:psoriasis |
1PhI |
CC-90006
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Pomalyst ( imnovid ( pomalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
4Reg. |
Pomalyst ( imnovid ( pomalidomide)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CAR-T (JCAR15) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
ALL( Accute Lymphoblastic Leukemia) |
2PhII |
CAR-T (JCAR15)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
ABRAXANE® |
Biodrugs/ Drugs |
Cancer |
Pancreatic:Adjuvant |
3PhIII |
ABRAXANE®
Therapeutic area:
Cancer
|
|
Celgene |
RPC4046 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Eosinophilic esophagitis |
2PhII |
RPC4046
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
IDHIFA (enasidenib) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
myelody syndromes (MDS(Newly diagnosed AML with an IDH2 mutation |
1PhI |
IDHIFA (enasidenib)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
AG-881 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute Myeloid Leukemia (AML)
Glioma |
1PhI |
AG-881
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
Thalomid / thalidomide celgene (Thalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
4Reg. |
Thalomid / thalidomide celgene (Thalidomide)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Luspatercept (ACE-536) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Others |
Myelodisplastic Syndromes (MDS)
Beta-thalassemia |
3PhIII |
Luspatercept (ACE-536)
Therapeutic area:
Blood and Lymphatic systems / Others
|
|
Celgene |
VIDAZA® (azacitidine for injection) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute myeloid laeukemia (AML) (>30% blasts) |
4Reg. |
VIDAZA® (azacitidine for injection)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma |
1PhI |
CC-486
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CD19 CAR-T (JCAR017) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Aggressive large B-cell lymphoma: Relapsed/refractory |
1PhI |
CD19 CAR-T (JCAR017)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
BCMA CAR T (JCARH125) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) |
1PhI |
BCMA CAR T (JCARH125)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
PPM Pleiotropic Pathway Modifier: CC-122 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Hepatocellular carcinoma |
2PhII |
PPM Pleiotropic Pathway Modifier: CC-122
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
PD-L1 Inhibitor: durvalumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML) |
2PhII |
PD-L1 Inhibitor: durvalumab
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Breast. metastatic nonsmall cell lung: advanced myelodysplastic syndromes ( MDS) : post hypomethylating agent (HMA) failure. |
2PhII |
CC-486
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
BCMA CAR-T (bb2121) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) |
1PhI |
BCMA CAR-T (bb2121)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC-92480 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
1PhI |
CC-92480
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Ozanimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis
Relapsing multiple sclerosis |
3PhIII |
Ozanimod
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Mongersen (GED 0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
3PhIII |
Mongersen (GED 0301)
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Celgene |
Anti-CD47 Antibody: CC-90002 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Solid Tumors
lymphoma: non-hogdkin lymphoma (NHL) |
1PhI |
Anti-CD47 Antibody: CC-90002
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
BET inhibitor: CC-90010 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
lymphoma. Non-hodgkin lymphoma (NHL) |
1PhI |
BET inhibitor: CC-90010
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
Citarinostat (ACY-241) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) relapsed/refractory |
1PhI |
Citarinostat (ACY-241)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
CC-93269 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) Relapsed/ refractory |
1PhI |
CC-93269
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Ozanimod |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Crohn`s disease |
3PhIII |
Ozanimod
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Luspatercept (ACE-536) |
Biodrugs/ Drugs |
Cancer |
Myelofibrosis: MF Anemia |
2PhII |
Luspatercept (ACE-536)
Therapeutic area:
Cancer
|
|
Celgene |
ISTODAX® (romidepsin) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Peripheral T-cell lymphoma:First-line |
3PhIII |
ISTODAX® (romidepsin)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
LSD1 Inhibitor: CC-90011 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
LSD1 Inhibitor: CC-90011
Therapeutic area:
Cancer
|
|
Celgene |
Fedratinib |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Myelofibrosis: MF anemia |
3PhIII |
Fedratinib
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
SOTATERCEPT (ACE-011) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Chronic kidney disease |
2PhII |
SOTATERCEPT (ACE-011)
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Abraxane (paclitaxel proteinbound particle for injectable susoension) ( Albumin-bound) /(paclitaxel formulated as albuminbound nanoparticles) |
Biodrugs/ Drugs |
Cancer |
Solid tumors , breast metastatic.
Nonsmall cell lung advanded (First line)
Pancratic metastatic ( First line)
gastric metastatic ( Japan) |
4Reg. |
Abraxane (paclitaxel proteinbound particle for injectable susoension) ( Albumin-bound) /(paclitaxel formulated as albuminbound nanoparticles)
Therapeutic area:
Cancer
|
|
Celgene |
CC 486 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma |
1PhI |
CC 486
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
OTEZLA® (apremilast) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
OTEZLA® (apremilast)
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
Marizomib |
Biodrugs/ Drugs |
Cancer |
solid tumors. Glioblastoma |
2PhII |
Marizomib
Therapeutic area:
Cancer
|
|
Celgene |
CC-220 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myeloma (MM) relapsed/refractory |
1PhI |
CC-220
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
ISTODAX ( romidepsin) for injection |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoma. Cutaneous T-cell Lymphoma (US). |
4Reg. |
ISTODAX ( romidepsin) for injection
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
ISTODAX® (romidepsin) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Peripheral T-cell lymphoma: relapsed/refractory (Japan) |
2PhII |
ISTODAX® (romidepsin)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
Tislelizumab |
Biodrugs/ Drugs |
Cancer |
solid tumors. non-small cell lung cancer. Hepatocellular carcinoma. Esophageal squamous cell carcinoma |
3PhIII |
Tislelizumab
Therapeutic area:
Cancer
|
|
Celgene |
REVLIMID® (lenalidomide) |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse large B-cell lymphoma (ABC subtype): First line
Indolent lymphoma: relapsed/refractory
Follicular lymphoma: first line |
3PhIII |
REVLIMID® (lenalidomide)
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Celgene |
CC-90001 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Fibrosis |
2PhII |
CC-90001
Therapeutic area:
Autoimmune & Inflammation
|
|
Celgene |
REVLIMID ( lenalidomida) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Multiple Myelome (MM): Relapsed/refractory
Newly diagnosed
Maintenance
Myelodyplastic syndromes (MDS) deletion 5q.
lymphoma: mantle cell lymphoma , relapsed/ refratory. |
4Reg. |
REVLIMID ( lenalidomida)
Therapeutic area:
Blood and Lymphatic systems
|
|
Celgene |
Morgensen (GED-0301) |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Ulcerative colitis |
2PhII |
Morgensen (GED-0301)
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
 |
Gilead Sciences |
Axicabtagene colileucel |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Indolent NHL |
2PhII |
Axicabtagene colileucel
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
GS-5745 (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Andecaliximab (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
1PhI |
Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
GS-9131 (NRTI) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
GS-9131 (NRTI)
Therapeutic area:
Infections
|
|
Gilead Sciences |
Filgotinib (JAK1 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Crohn's Disease and Ulcerative colitis |
2PhII |
Filgotinib (JAK1 inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
MCL |
2PhII |
KTE-C19
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Momelotinib |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
2PhII |
Momelotinib
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Entosplenitib (Syk inhibitor) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Hematological malignances |
2PhII |
Entosplenitib (Syk inhibitor)
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir |
Biodrugs/ Drugs |
Infections |
HIV/AIDS - PreExposure Profilaxis |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir
Therapeutic area:
Infections
|
|
Gilead Sciences |
Presatovir ( Fusion inhibitor) |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Respiratory Syncytial Virus |
2PhII |
Presatovir ( Fusion inhibitor)
Therapeutic area:
Respiratory and Pulmonary system
|
|
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Adult ALL |
1PhI |
KTE-C19
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Digestive System |
Nonalcoholic steatohaepatitis |
2PhII |
GS-4997 (ASK-1 inhibitor)
Therapeutic area:
Digestive System
|
|
Gilead Sciences |
Alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Alafenamide STR
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-9876 ( Syk Inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Sjogren's Syndrome |
2PhII |
GS-9876 ( Syk Inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
KTE-C19 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Pedriatic ALL |
1PhI |
KTE-C19
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Digestive System |
Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis |
2PhII |
Simtuzumab
Therapeutic area:
Digestive System
|
|
Gilead Sciences |
GS-9688 (TLR-8 Agonist) |
Biodrugs/ Drugs |
Infections |
HBV |
1PhI |
GS-9688 (TLR-8 Agonist)
Therapeutic area:
Infections
|
|
Gilead Sciences |
Emtricitabine/Tenofovir alafenamide FDC |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-9876 (Syk inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Lupus |
2PhII |
GS-9876 (Syk inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
ERK Inhibitor |
Biodrugs/ Drugs |
Cancer |
Cancer |
1PhI |
ERK Inhibitor
Therapeutic area:
Cancer
|
|
Gilead Sciences |
KITE-585 ( anti-BCMA) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
MM |
1PhI |
KITE-585 ( anti-BCMA)
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Simtuzumab |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiopathic pulmonary fibrosis |
2PhII |
Simtuzumab
Therapeutic area:
Respiratory and Pulmonary system
|
|
Gilead Sciences |
Selonsertib ( ASK-1 Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
3PhIII |
Selonsertib ( ASK-1 Inhibitor)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
3PhIII |
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-4875 (TPL2 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Inflammatory Bowel |
1PhI |
GS-4875 (TPL2 inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Vestalimod ( GS-9620, TRL-7 agonist) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
Vestalimod ( GS-9620, TRL-7 agonist)
Therapeutic area:
Infections
|
|
Gilead Sciences |
KITE-718 ( MAGE A3/A6) |
Biodrugs/ Drugs |
Cancer |
Solid tumor. |
1PhI |
KITE-718 ( MAGE A3/A6)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
Selonsertib ( ASK-1 Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Alcoholic Hepatitis |
2PhII |
Selonsertib ( ASK-1 Inhibitor)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Remdesivir ( Gs-5734, Nuc. Inhibitor) |
Biodrugs/ Drugs |
Infections |
Ebola Virus infection |
2PhII |
Remdesivir ( Gs-5734, Nuc. Inhibitor)
Therapeutic area:
Infections
|
|
Gilead Sciences |
Tirabrutinib (BTK inhibitor) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
B-cell malignancies |
2PhII |
Tirabrutinib (BTK inhibitor)
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
Andecaliximab (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Cancer |
Gastric cancer |
3PhIII |
Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area:
Cancer
|
|
Gilead Sciences |
GS-62'7 (capsid inhibitor) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
GS-62'7 (capsid inhibitor)
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
2PhII |
GS-9674 (FXR Agonist)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
GS-5806 (fusion inhibitor) |
Biodrugs/ Drugs |
Infections
Respiratory and Pulmonary system |
Respiratory syncytial virus |
2PhII |
GS-5806 (fusion inhibitor)
Therapeutic area:
Infections / Respiratory and Pulmonary system
|
|
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Primary Bilinary Cirrhosis |
2PhII |
GS-9674 (FXR Agonist)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
GS-6615 (late sodium current inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Ventricular tachycardia / Ventricular fibrillation |
2PhII |
GS-6615 (late sodium current inhibitor)
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
GS-9674 (FXR Agonist) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Primary Sclerosing Cholangit |
2PhII |
GS-9674 (FXR Agonist)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
GS-9722 (bNab) |
Biodrugs/ Drugs |
Infections |
HIV/AIDS |
1PhI |
GS-9722 (bNab)
Therapeutic area:
Infections
|
|
Gilead Sciences |
GS-4997 (ASK-1 inhibitor) |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Pulmonary arterial hypertension |
2PhII |
GS-4997 (ASK-1 inhibitor)
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Gilead Sciences |
GS-0976 ( ACC Inhibitor) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
NASH |
2PhII |
GS-0976 ( ACC Inhibitor)
Therapeutic area:
Metabolic / Endocrinology
|
|
Gilead Sciences |
Axicabtagene ciloleucel |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
DLBCL ,PMBCL & TFL |
3PhIII |
Axicabtagene ciloleucel
Therapeutic area:
Blood and Lymphatic systems
|
|
Gilead Sciences |
GS-5745 (MMP9 mAb inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
GS-5745 (MMP9 mAb inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
|
Gilead Sciences |
Filgotinib (JAK1 inhibitor) |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid Arthritis |
3PhIII |
Filgotinib (JAK1 inhibitor)
Therapeutic area:
Autoimmune & Inflammation
|
 |
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
8p11 MPN |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Epacadostat |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer (with pembrolizumab) (In collaboration with Merck) |
2PhII |
Epacadostat
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Ruxolitinib |
Biodrugs/ Drugs |
Cancer |
Chronic graft-versus-host disease |
3PhIII |
Ruxolitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Follicular lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCB01158 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Co-development with Calithera) |
2PhII |
INCB01158
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Marginal zone lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCAGN1876 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Discovery alliance with Agenus) |
2PhII |
INCAGN1876
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Parsaclisib |
Biodrugs/ Drugs |
Cancer |
Mantle cell lymphoma |
2PhII |
Parsaclisib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCAGN1949 |
Biodrugs/ Drugs |
Cancer |
Solid tumors (Discovery alliance with Agenus) |
2PhII |
INCAGN1949
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
MSI-H endometrial cancer (In collaboration with MacroGenics) |
1PhI |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Merkel cell carcinoma (In collaboration with MacroGenics) |
2PhII |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Acute graft-versus-host disease |
3PhIII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
INCMGA0012 |
Biodrugs/ Drugs |
Cancer |
Anal cancer (In collaboration with MacroGenics) |
2PhII |
INCMGA0012
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Chronic graft-versus-host disease |
3PhIII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Itacitinib |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) |
2PhII |
Itacitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Ruxolitinib |
Biodrugs/ Drugs |
Cancer |
Acute graft-versus-host disease |
3PhIII |
Ruxolitinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Bladder cancer |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
|
Incyte Biosciences Iberia |
Pemigatinib |
Biodrugs/ Drugs |
Cancer |
Cholangiocarcinoma |
2PhII |
Pemigatinib
Therapeutic area:
Cancer
|
 |
Merck |
M9241 (NHS-IL12) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2PhII |
M9241 (NHS-IL12)
Therapeutic area:
Cancer
|
|
Merck |
Avelumab |
Biodrugs/ Drugs |
Cancer |
Merkel Cell 1L |
2PhII |
Avelumab
Therapeutic area:
Cancer
|
|
Merck |
Atacicept |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Systemic lupus erythematosus and IgA nephropathy |
2PhII |
Atacicept
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck |
Tepotinib |
Biodrugs/ Drugs |
Cancer |
non-Smaill Lung cancer and hepatocellular |
2PhII |
Tepotinib
Therapeutic area:
Cancer
|
|
Merck |
Evobrutinib BTK inhibitor |
Biodrugs/ Drugs |
Central Nervous System |
Multiple Sclerosis |
2PhII |
Evobrutinib BTK inhibitor
Therapeutic area:
Central Nervous System
|
|
Merck |
M7824 / TGF beta trap |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cancer |
Solid tumors |
1PhI |
M7824 / TGF beta trap
Therapeutic area:
Autoimmune & Inflammation / Cancer
|
 |
Merck KGaA |
Abituzumab |
Biodrugs/ Drugs |
Cancer |
Colorectal Cancer, Prostate cancer, solid tumours |
2PhII |
Abituzumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Evofosfamida |
Biodrugs/ Drugs |
Cancer
Dermatology
Digestive System |
Pancreas, cancer, sarcoma |
4Reg. |
Evofosfamida
Therapeutic area:
Cancer / Dermatology / Digestive System
|
|
Merck KGaA |
Avelumab |
Biodrugs/ Drugs |
Cancer |
Several types of cancer |
3PhIII |
Avelumab
Therapeutic area:
Cancer
|
|
Merck KGaA |
Atacicept |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Autoinmune disease |
2PhII |
Atacicept
Therapeutic area:
Autoimmune & Inflammation
|
|
Merck KGaA |
Pimasertib |
Biodrugs/ Drugs |
Cancer |
Colorectal Cancer, Pancreas, Melanoma, solid tumours and ovarian cancer |
4Reg. |
Pimasertib
Therapeutic area:
Cancer
|
 |
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced melanoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V114 |
Vaccines |
Infections |
Paedriatric Prevention of pneumococal infection with V114 |
3PhIII |
V114
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab vs chemotherapy in patients with advanced melanoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for Squamous Non Small cell Lubng cancer |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
SItagliptin |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes and milf renal imparment |
3PhIII |
SItagliptin
Therapeutic area:
Metabolic / Endocrinology
|
|
MSD |
MK1654 |
Biodrugs/ Drugs |
Infections |
VRS prevention in preterm infants |
2PhII |
MK1654
Therapeutic area:
Infections
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of CMV disease in D+/R- kidney transplant recipients |
3PhIII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
SIVEXTRO |
Biodrugs/ Drugs |
Infections |
Subjects 12 to <18 Years with complicated Skin and Soft Tissue Infections (cSSTI) |
3PhIII |
SIVEXTRO
Therapeutic area:
Infections
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients |
1PhI |
ZERBAXA
Therapeutic area:
Respiratory and Pulmonary system
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for Second Line Therapy of Advanced melanoma post anti-PD1b inhibitor |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Gardasil 9 |
Vaccines |
Infections |
Prevention of HPV infection with Gardasil 9 in adult women 27-46 |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients |
3PhIII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for non Squamous Non Small cell Lubng cancer |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
mk7655A |
Biodrugs/ Drugs |
Infections |
Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma |
3PhIII |
mk7655A
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
In combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Olaparib |
Biodrugs/ Drugs |
Cancer |
Olaparib in Participants with solid tumors Previously Treated |
2PhII |
Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Trastuzumab + Chemotherapy with/without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. |
3PhIII |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Stereotactic Body Radiotherapy (SBRT) with Pembrolizumab or Placebo |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
BET Inhibitor |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
BET Inhibitor
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with lenalidomide and dexamethasone in subjects Multiple Myeloma |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
first Line Study of Pembrolizumab +/- Ipilimumab in NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Progressive or recurrent Intermediate or High risk, Non-muscle invasive Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in advanced Merkel Cell Carcinoma (MCC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Study of Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Neoadjuvant treatment Platinum Doublet Chemotherapy +/-Pembrolizumab followed by Surgery |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Lenvatinib |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
20 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZINPLAVA |
Biodrugs/ Drugs |
Infections |
in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) |
3PhIII |
ZINPLAVA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Prevymis (Letermovir) |
Biodrugs/ Drugs |
Infections |
Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT) |
2PhII |
Prevymis (Letermovir)
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gardasil 9 |
Vaccines |
Infections |
VPH in preadolescents and adolescents |
3PhIII |
Gardasil 9
Therapeutic area:
Infections
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric Subjects with nosocomial pneumonia |
1PhI |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab with or without Chemotherapy as First-line Treatment in Participants With HER2 negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II, Pembrolizumab combined with chemotherapy as a First line treatment for NSCLC. |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Epacadostat |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
RIG-I |
Biodrugs/ Drugs |
Cancer |
Advanced/Metastatic or Recurrent Solid Tumors |
1PhI |
RIG-I
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
PD-L1 Strong Metastatic Non-Small Cell Lung Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gefapixant |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Chronic cough |
2PhII |
Gefapixant
Therapeutic area:
Respiratory and Pulmonary system
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line etoposide/platinum with or without pembrolizumab in extensive stage small cell lung cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V160 |
Vaccines |
Infections |
Prevention CMVin women 16-35 dosis vx 3 dosis |
2PhII |
V160
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + lenvatinib versus docetaxel for metastatic Non-Small Cell Lung Cancer after platinum doublet chemotherapy and immunotherapy |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced/Unresectable or Metastatic Urothelial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase II (biomarker directed) Pembrolizumab Based Combination Therapy for Advanced Non-Small Cell Lung Cancer |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Adult Patients with Ventilated Nosocomial Pneumonia |
3PhIII |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Fosaprepitant |
Biodrugs/ Drugs |
Cancer |
Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy |
3PhIII |
Fosaprepitant
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab + Chemotherapy + Radiotherapy in Stage III NSCLC |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Gefapixant |
Biodrugs/ Drugs |
Women´s health |
Moderate to Severe Endometriosis-related Pain |
2PhII |
Gefapixant
Therapeutic area:
Women´s health
|
|
MSD |
LAG3 |
Biodrugs/ Drugs |
Cancer |
4 Select Advanced Solid Tumors |
1PhI |
LAG3
Therapeutic area:
Cancer
|
|
MSD |
Elbasvir/Grazoprevir |
Biodrugs/ Drugs |
Infections |
Chronic Hepatitis C |
3PhIII |
Elbasvir/Grazoprevir
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
ZERBAXA |
Biodrugs/ Drugs |
Infections |
Pediatric Subjects with Complicated Intra-Abdominal Infection |
2PhII |
ZERBAXA
Therapeutic area:
Infections
|
|
MSD |
mk7655A |
Biodrugs/ Drugs |
Infections |
Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia |
3PhIII |
mk7655A
Therapeutic area:
Infections
|
|
MSD |
Vericiguat |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Heart failure with reduced ejection Fraction |
3PhIII |
Vericiguat
Therapeutic area:
Cardiovascular and circulatory systems
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III Pembro + Chemotherapy in Persistent, Recurrent or Metastatic Cervical Cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Triple-Negative Breast Cancer (mTNBC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced HCC |
3PhIII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with relapsed of refractory classical hodgkin lymphona |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) |
2PhII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
V920 |
Vaccines |
Infections |
Three consistency lot doses and high dose of rVSV-ZEBOV-GiP (V920 ebola vaccine) in Healthy Adults |
3PhIII |
V920
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab/Olaparib |
Biodrugs/ Drugs |
Cancer |
Phase III first line chemotherapy plus pembrolizumab + olaparib for BRCA non-mutated advanced EOC (epitelial ovarian cancer) |
3PhIII |
Pembrolizumab/Olaparib
Therapeutic area:
Cancer
|
|
MSD |
Inactivated VZV Vaccine |
Vaccines |
Blood and Lymphatic systems
Cancer |
Adult Patients with Solid Tumor or Hematologic Malignancy |
3PhIII |
Inactivated VZV Vaccine
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
MSD |
Anacetrapib |
Biodrugs/ Drugs |
Cancer |
First line study of pembrolizumab +/- epacadostat in NSCLC |
3PhIII |
Anacetrapib
Therapeutic area:
Cancer
|
|
MSD |
Posaconazole |
Biodrugs/ Drugs |
Infections |
Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia |
1PhI |
Posaconazole
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma treatment naïve |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Doravirine |
Biodrugs/ Drugs |
Infections |
HIV Infection |
3PhIII |
Doravirine
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil as First Line treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Phase III extension study for participants with advanced tumors in pembrolizumab trials |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
SIVEXTRO |
Biodrugs/ Drugs |
Infections |
Ventilated Gram-positive Nosocomial Pneumonia |
3PhIII |
SIVEXTRO
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
First line study of pembrolizumab +/- epacadostat in NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab/Lenvatinib |
Biodrugs/ Drugs |
Cancer |
Lenvatinib plus Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors |
2PhII |
Pembrolizumab/Lenvatinib
Therapeutic area:
Cancer
|
|
MSD |
V114 |
Vaccines |
Infections |
Pneumoccoco in healthy adults 50 years of age or older |
3PhIII |
V114
Therapeutic area:
Infections
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Golimumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Non-radiographic axial Spondyloarthritis |
4Reg. |
Golimumab
Therapeutic area:
Autoimmune & Inflammation
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pembrolizumab in Combination Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
10 Select Advanced Solid Tumors |
1PhI |
Pembrolizumab
Therapeutic area:
Cancer
|
|
MSD |
Pembrolizumab |
Biodrugs/ Drugs |
Cancer |
Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC |
3PhIII |
Pembrolizumab
Therapeutic area:
Cancer
|
 |
Novo Nordisk Pharma |
Insulin LA287 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Insulin LA287
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide NASH |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Non-alcoholic steatohepatitis |
2PhII |
Semaglutide NASH
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Monoclonal antibody anti Il-21 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 |
2PhII |
Monoclonal antibody anti Il-21
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Prandial Bioedge |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and 2 |
1PhI |
Prandial Bioedge
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Oral semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Oral semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Somapacitan(Long-acting growth hormone) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Growth hormone deficiency |
3PhIII |
Somapacitan(Long-acting growth hormone)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide obesidad |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
3PhIII |
Semaglutide obesidad
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Concizumab |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A and B |
2PhII |
Concizumab
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
AM833 (amilyn analogue) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
AM833 (amilyn analogue)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Semaglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
3PhIII |
Semaglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
G530L (glucagon analogue/liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
G530L (glucagon analogue/liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 in paediatric population |
3PhIII |
Liraglutide
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
PYY1562 (analogue peptid YY) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
1PhI |
PYY1562 (analogue peptid YY)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Nonacog beta pegol |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia B |
4Reg. |
Nonacog beta pegol
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
IDegAsp (combination insulin degludec + insulin aspart) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 and type 1 |
4Reg. |
IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
N8-GP (glycopegylated recombinant FVIII) |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
N8-GP (glycopegylated recombinant FVIII)
Therapeutic area:
Blood and Lymphatic systems
|
|
Novo Nordisk Pharma |
IDegLira (combination insulin degludec + liraglutide) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 2 |
4Reg. |
IDegLira (combination insulin degludec + liraglutide)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Faster-acting insulin aspart (FIAsp) |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes type 1 and type 2 |
4Reg. |
Faster-acting insulin aspart (FIAsp)
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Liraglutide 3mg |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity |
4Reg. |
Liraglutide 3mg
Therapeutic area:
Metabolic / Endocrinology
|
|
Novo Nordisk Pharma |
Turoctocog alfa |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
4Reg. |
Turoctocog alfa
Therapeutic area:
Blood and Lymphatic systems
|
 |
Roche |
BITOPERTIN |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia |
3PhIII |
BITOPERTIN
Therapeutic area:
Central Nervous System
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
4Reg. |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
EM MS BIOMARKER |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM MS BIOMARKER
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Malignant neoplams of lymphoid haematopoietic |
1PhI |
CD20 CD3 TDB
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
selicrelumab |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
selicrelumab
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
BRAF KIN INH (2) |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
BRAF KIN INH (2)
Therapeutic area:
Cancer
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
ulcerative colitis |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Other necrotizing vasculopathies |
3PhIII |
MABTHERA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
TIRAGOLUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
TIRAGOLUMAB
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
4Reg. |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthristis ( juvenile) |
4Reg. |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
2PhII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
FORTOVASE |
Biodrugs/ Drugs |
Infections |
HIV disease unspecified |
2PhII |
FORTOVASE
Therapeutic area:
Infections
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Musculoskeletal Disorders |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
1PhI |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Non-hodgkin's lymphoma |
1PhI |
CD20 CD3 TDB
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
SMN2 splicer (2) |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Spinal muscular atrophy and related syndromes |
3PhIII |
SMN2 splicer (2)
Therapeutic area:
Musculoskeletal Disorders
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
4Reg. |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhIII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
CEA IL2V |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA IL2V
Therapeutic area:
Cancer
|
|
Roche |
FAP 4-1BBL iMAb |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
FAP 4-1BBL iMAb
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Pemphigus |
3PhIII |
MABTHERA
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and unspecified parts of biliary tract |
3PhIII |
GAZYVA
Therapeutic area:
Cancer
|
|
Roche |
HERCEPTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bladder |
2PhII |
HERCEPTIN
Therapeutic area:
Cancer
|
|
Roche |
TIRAGOLUMAB |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
2PhII |
TIRAGOLUMAB
Therapeutic area:
Cancer
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic sclerosis |
3PhIII |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
MabThera |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Follicular ( nodular) non-hodgkin's lymphoma |
3PhIII |
MabThera
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Metastases |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
OX40
Therapeutic area:
Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
colorectal cancer |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
Tau Mab (37D3) |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
Tau Mab (37D3)
Therapeutic area:
Central Nervous System
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
LEBRIKIZUMAB |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Other diseases of upper respiratory tract |
2PhII |
LEBRIKIZUMAB
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
triple negative breast cancer |
3PhIII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
FAP IL2V FP |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
FAP IL2V FP
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
PICTILISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
PICTILISIB
Therapeutic area:
Cancer
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
Myostatin |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Duchenne muscular dystrophy |
3PhIII |
Myostatin
Therapeutic area:
Musculoskeletal Disorders
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
GPC3 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of liver |
2PhII |
GPC3 MAB
Therapeutic area:
Cancer
|
|
Roche |
LIFASTUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of ovary |
2PhII |
LIFASTUZUMAB VEDOTIN
Therapeutic area:
Cancer
|
|
Roche |
VEFG- ANG2 Bsb |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
3PhIII |
VEFG- ANG2 Bsb
Therapeutic area:
Ophthalmology and optometry
|
|
Roche |
ALEGLITAZAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
ALEGLITAZAR
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Plasma cell neoplasm |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
PLGF MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
PLGF MAB
Therapeutic area:
Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Pancreatic cancer |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
breast cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Acute myocardial infarction |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
MERICITABINE |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
MERICITABINE
Therapeutic area:
Infections
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
MIRCERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Chronic renal failure anemia |
2PhII |
MIRCERA
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
FAP IL2V FP |
Biodrugs/ Drugs |
Cancer |
non-Small cell lung cancer |
2PhII |
FAP IL2V FP
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Malignant neoplasms of lymphoid haematopoietic + |
3PhIII |
GAZYVA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of kidney except renal pelvis |
2PhII |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
SEMBRAGILINE |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
SEMBRAGILINE
Therapeutic area:
Central Nervous System
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
Asyn MAb |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson's disease |
2PhII |
Asyn MAb
Therapeutic area:
Central Nervous System
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Multiple Sclerosis |
4Reg. |
OCREVUS
Therapeutic area:
Central Nervous System
|
|
Roche |
PERJETA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
PERJETA
Therapeutic area:
Cancer
|
|
Roche |
HPV16 TI |
Biodrugs/ Drugs |
Infections |
Viral agents as cause of diseases classified to other |
2PhII |
HPV16 TI
Therapeutic area:
Infections
|
|
Roche |
NEORECORMON |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Anaemia in neoplastic disease |
2PhII |
NEORECORMON
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
XOLAIR |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
other diseases of upper respiratory tract |
3PhIII |
XOLAIR
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
COBIMETINIB |
Biodrugs/ Drugs |
Cancer |
Malignant melanoma of skin |
3PhIII |
COBIMETINIB
Therapeutic area:
Cancer
|
|
Roche |
Esbriet |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Idiophatic pulmonary fibrosis |
2PhII |
Esbriet
Therapeutic area:
Respiratory and Pulmonary system
|
|
Roche |
CEACAM5 CEA TCB |
Biodrugs/ Drugs |
Cancer |
Solid tumor |
1PhI |
CEACAM5 CEA TCB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Head and neck cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
DALCETRAPIB |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Atherosclerosis |
3PhIII |
DALCETRAPIB
Therapeutic area:
Cardiovascular and circulatory systems / Metabolic / Endocrinology
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of brain |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
mPI3K alpha inh |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1PhI |
mPI3K alpha inh
Therapeutic area:
Cancer
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Other malignant neoplasms of skin |
1PhI |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
GAZYVA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic lupus erythematosus |
2PhII |
GAZYVA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
MABTHERA |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Other + unspecif. types of non-Hodgkin's lymphoma |
3PhIII |
MABTHERA
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
BASIMGLURANT |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Fragile X Syndrome |
2PhII |
BASIMGLURANT
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ALECENSA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECENSA
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
breast cancer |
4Reg. |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Primary progresive multiple sclerosis |
3PhIII |
OCREVUS
Therapeutic area:
Central Nervous System
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
3PhIII |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
PATECLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
PATECLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
HCV POL INH PRO |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
HCV POL INH PRO
Therapeutic area:
Infections
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Irritable bowel syndrome |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
FENEBRUTINIB |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
systemic lupus erythematosus |
2PhII |
FENEBRUTINIB
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
Cergutuzumab amunaleukin |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
Cergutuzumab amunaleukin
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Hepatocellular carcinoma |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
other unspecificed types of non-hodgkin's lymphoma |
2PhII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
SERD (2) |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1PhI |
SERD (2)
Therapeutic area:
Cancer
|
|
Roche |
EM RA PRED DEV |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
1PhI |
EM RA PRED DEV
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
HEMLIBRA |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemophilia A |
3PhIII |
HEMLIBRA
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
PEGASYS |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
3PhIII |
PEGASYS
Therapeutic area:
Infections
|
|
Roche |
CMV ANTI |
Biodrugs/ Drugs |
Infections |
Cytomegaloviral disease |
2PhII |
CMV ANTI
Therapeutic area:
Infections
|
|
Roche |
ALPHA7 NIC AGO |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2PhII |
ALPHA7 NIC AGO
Therapeutic area:
Central Nervous System
|
|
Roche |
ALECENSA |
Biodrugs/ Drugs |
Cancer |
Non-small cell lung cancer |
4Reg. |
ALECENSA
Therapeutic area:
Cancer
|
|
Roche |
VANUCIZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
VANUCIZUMAB
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Cervical cancer |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Central Nervous System |
Relapsing-remitting multiple sclerosis |
3PhIII |
OCREVUS
Therapeutic area:
Central Nervous System
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Lymphoid leukaemia |
3PhIII |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
IGF1R MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
IGF1R MAB
Therapeutic area:
Cancer
|
|
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Follicular (nodular) non-Hodgkin's lymphoma |
2PhII |
POLATUZUMAB VEDOTIN
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
DSTA4637S |
Biodrugs/ Drugs |
Infections |
Bacterial infection of unespecified site |
1PhI |
DSTA4637S
Therapeutic area:
Infections
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
kidney cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
LAMPALIZUMAB |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinal disorders other |
4Reg. |
LAMPALIZUMAB
Therapeutic area:
Ophthalmology and optometry
|
|
Roche |
PARSATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
PARSATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
APITOLISIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
APITOLISIB
Therapeutic area:
Cancer
|
|
Roche |
GANTENERUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
GANTENERUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
Idasanutlin |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Leukaemia Acute |
3PhIII |
Idasanutlin
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Ovarian cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
SERD(3) (9545) |
Biodrugs/ Drugs |
Cancer |
breast cancer metastatic |
1PhI |
SERD(3) (9545)
Therapeutic area:
Cancer
|
|
Roche |
ETROLIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease |
3PhIII |
ETROLIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Digestive System
|
|
Roche |
herceptin |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhIII |
herceptin
Therapeutic area:
Cancer
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
TAMIFLU |
Biodrugs/ Drugs |
Infections |
Influenza |
1PhI |
TAMIFLU
Therapeutic area:
Infections
|
|
Roche |
CRENEZUMAB |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
3PhIII |
CRENEZUMAB
Therapeutic area:
Central Nervous System
|
|
Roche |
ANTI-INFLUENZA A |
Biodrugs/ Drugs |
Infections |
Influenza |
2PhII |
ANTI-INFLUENZA A
Therapeutic area:
Infections
|
|
Roche |
Balovaptan |
Biodrugs/ Drugs |
Central Nervous System |
Autism |
3PhIII |
Balovaptan
Therapeutic area:
Central Nervous System
|
|
Roche |
VENETOCLAX |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Diffuse non-Hodgkin's lymphoma, unspecified |
1PhI |
VENETOCLAX
Therapeutic area:
Blood and Lymphatic systems / Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
OCREVUS |
Biodrugs/ Drugs |
Cancer |
Renal cancer carncinoma |
3PhIII |
OCREVUS
Therapeutic area:
Cancer
|
|
Roche |
XOLAIR |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Dermatitis (Allergic Contact) |
3PhIII |
XOLAIR
Therapeutic area:
Autoimmune & Inflammation / Dermatology
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
plasma cell neoplasm |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lungs |
4Reg. |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
herceptin |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
4Reg. |
herceptin
Therapeutic area:
Cancer
|
|
Roche |
OCRELIZUMAB |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Systemic lupus erythematosus |
3PhIII |
OCRELIZUMAB
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
TASPOGLUTIDE |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Diabetes Mellitus |
3PhIII |
TASPOGLUTIDE
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
DANOPREVIR |
Biodrugs/ Drugs |
Infections |
Chronic viral haepatitis |
2PhII |
DANOPREVIR
Therapeutic area:
Infections
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of cervix uteri |
2PhII |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
BET |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
1PhI |
BET
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
CD40 IMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CD40 IMAB
Therapeutic area:
Cancer
|
|
Roche |
AVASTIN |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site. |
4Reg. |
AVASTIN
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
3PhIII |
ACTEMRA
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
TARCEVA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of pancreas |
2PhII |
TARCEVA
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
TASELISIB |
Biodrugs/ Drugs |
Cancer |
Breast Cancer |
3PhIII |
TASELISIB
Therapeutic area:
Cancer
|
|
Roche |
IMGATUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IMGATUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
IL22 Fc |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Other disorders involving the immune mechanism |
1PhI |
IL22 Fc
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
PDL1 MAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
PDL1 MAB
Therapeutic area:
Cancer
|
|
Roche |
VALCYTE |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Transplanted organ and tissue status (Excl. complications) |
3PhIII |
VALCYTE
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
2PhII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
CEA CD3 TCB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CEA CD3 TCB
Therapeutic area:
Cancer
|
|
Roche |
cadherin-11 MAb |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Rheumatoid arthritis |
2PhII |
cadherin-11 MAb
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
OX40 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
4Reg. |
OX40
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Peripheral Vascular Diseases |
3PhIII |
ACTEMRA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of other and ill-defined sites |
2PhII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
Renal cell carcinoma |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
Venclexta |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's Lymphoma |
2PhII |
Venclexta
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
IL22 Fc |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Ulcerative colitis |
2PhII |
IL22 Fc
Therapeutic area:
Autoimmune & Inflammation
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
XELODA |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of colon/rectum |
3PhIII |
XELODA
Therapeutic area:
Cancer
|
|
Roche |
DULIGOTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
2PhII |
DULIGOTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ERIVEDGE
Therapeutic area:
Cancer
|
|
Roche |
COTELLIC |
Biodrugs/ Drugs |
Cancer |
Colorectal cancer |
3PhIII |
COTELLIC
Therapeutic area:
Cancer
|
|
Roche |
CIF MEK INH |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
1PhI |
CIF MEK INH
Therapeutic area:
Cancer
|
|
Roche |
CD20 CD3 TDB |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
1PhI |
CD20 CD3 TDB
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
POLATUZUMAB VEDOTIN |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Diffuse non-hodgkin's lymphoma |
3PhIII |
POLATUZUMAB VEDOTIN
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Thyrotoxicosis (hyperthyroidism) |
3PhIII |
ACTEMRA
Therapeutic area:
Metabolic / Endocrinology
|
|
Roche |
IPATASERTIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of prostate |
2PhII |
IPATASERTIB
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm without specification of site |
2PhII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
ALECTINIB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of bronchus and lung |
3PhIII |
ALECTINIB
Therapeutic area:
Cancer
|
|
Roche |
Tecentriq |
Biodrugs/ Drugs |
Cancer |
triple negative breast cancer |
3PhIII |
Tecentriq
Therapeutic area:
Cancer
|
|
Roche |
Venclexta |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Lymphoid leukaemia |
3PhIII |
Venclexta
Therapeutic area:
Blood and Lymphatic systems
|
|
Roche |
LUMRETUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of breast |
1PhI |
LUMRETUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ACTEMRA |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Giant Cel arteritis |
3PhIII |
ACTEMRA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Roche |
KADCYLA |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
3PhIII |
KADCYLA
Therapeutic area:
Cancer
|
|
Roche |
ONARTUZUMAB |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasm of stomach |
3PhIII |
ONARTUZUMAB
Therapeutic area:
Cancer
|
|
Roche |
ZELBORAF |
Biodrugs/ Drugs |
Cancer |
Malignant neoplasms |
3PhIII |
ZELBORAF
Therapeutic area:
Cancer
|
|
Roche |
EM ACTEMAB RA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
EM ACTEMAB RA
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
Roche |
ERIVEDGE |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cancer |
Other disorders involving the immune mechanism |
2PhII |
ERIVEDGE
Therapeutic area:
Autoimmune & Inflammation / Cancer
|
 |
TiGenix |
Cx611 |
Gene / Cell Therapy |
Autoimmune & Inflammation
Musculoskeletal Disorders |
Rheumatoid arthritis |
2PhII |
Cx611
Therapeutic area:
Autoimmune & Inflammation / Musculoskeletal Disorders
|
|
TiGenix |
Cx611 |
Gene / Cell Therapy |
Autoimmune & Inflammation
Infections |
Severe sepsis |
2PhII |
Cx611
Therapeutic area:
Autoimmune & Inflammation / Infections
|
|
TiGenix |
Cx621 |
Gene / Cell Therapy |
Autoimmune & Inflammation |
No human data available. Development currently on hold. |
1PhI |
Cx621
Therapeutic area:
Autoimmune & Inflammation
|